Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15104421 | 0.89 | DDB1 (0.50) | ESR2MAPK1NR1H2UCHL1DDB1 | |
| SCHEMBL10289745 | 0.89 | ESR2 (0.53) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL5774734 | 0.88 | UCHL1 (0.53) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL29554603 | 0.88 | UCHL1 (0.53) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL17687053 | 0.87 | NR1H2 (0.53) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL22530017 | 0.87 | ESR2 (0.51) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL5778372 | 0.87 | ESR2 (0.51) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL29421814 | 0.87 | ESR2 (0.51) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL30606082 | 0.87 | NR1H2 (0.53) | ESR2MAPK1NR1H2UCHL1SCN9A | |
| SCHEMBL22366367 | 0.84 | ESR2 (0.51) | ESR2MAPK1NR1H2UCHL1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | ESR2 363/4885MAPK1 2336/4885NR1H2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.